CLYM
NASDAQ HealthcareClimb Bio, Inc. - Common Stock
Biotechnology
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
๐ Market Data
| Price | $17.44 |
|---|---|
| Volume | 1,825,378 |
| Market Cap | 1.00B |
| Beta | 0.080 |
| RSI (14-Day) | 80.2 Overbought |
| 200-Day MA | $7.67 |
| 50-Day MA | $12.73 |
| 52-Week High | $17.52 |
| 52-Week Low | $1.54 |
| Forward P/E | -16.52 |
| Price / Book | 4.18 |
๐ฏ Investment Strategy Scores
CLYM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (95/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CLYM in your text
Paste any article, transcript, or post โ the tool will extract CLYM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.